[Correspondence] Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

We thank Delaloge and DeForceville1 for raising several important points in their Comment on results from LOTUS,2 a randomised, phase 2 trial investigating the addition of ipatasertib to paclitaxel as first-line therapy for metastatic triple-negative breast cancer. Specifically, they expressed concern over tissue-based diagnostics, given the spatial and temporal heterogeneity observed in triple-negative breast cancer. They remarked that if, as suggested in LOTUS, genomic alterations are the preferred biomarker, circulating tumour (ct) DNA methods might be useful in improving therapeutic targeting.

http://ift.tt/2znEHmi